Search Results

11 - 13 of 13 items :

  • "performance" x
  • Internal Medicine x
  • Paediatric Haematology and Oncology x
  • Life Sciences x
Clear All
Plerixafor for patients who fail cytokine-or chemotherapy-based stem cell mobilization: Results of a prospective study by the Polish Lymphoma Research Group (PLRG)

/μL after 1st dose of plerixafor (median, range) 25.5 (0.2-708.4) 13.2 (0.2-57) 28.3 (20-75) 68.1 (11-708.4) Fold increase 3.3 (0.3-155) 6.1 (0.7-155) 4.5 (2.2-8.3) 2.1 (0.3-7.7) The analysis was restricted to 81 patients with available data. Factors affecting efficacy of mobilization with the use of plerixafor A univariate analysis was performed to evaluate associations of potential prognostic factors with the rate of successful mobilization. The following factors were analyzed: age, performance status, type of mobilization

Open access
Prognostic value of soluble angiotensin II receptor 1 and soluble angiotensin converting enzyme (CD 143) in patients with acute leukemia

characteristic (ROC), carried out using MedCalc statistical software, was used to evaluate the diagnostic and prognostic accuracy of a test to correctly pick cured and non-cured subjects. The larger the area under the curve (AUC) i.e. closer to 1, the better the performance of a diagnostic test. Youden index was used to find the cut-of point i.e. the point that gives maximum correct classification. At this cut-off point, sensitivity; defined as the probability that the test is positive in patients with the disease and specificity; defined as the probability that the test is

Open access
Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2018/2019

leczenia starszego chorego na szpiczaka jest uzyskanie długiego całkowitego czasu przeżycia i zapewnienie możliwie dobrej jakości życia W optymalnych warunkach wskazana jest współpraca z lekarzem geriatrą. Tabela XX Algorytm leczenia chorych na szpiczaka ze względu na stan ogólny Table XX. Treatment algorithm acc. to performance status of multiple myeloma patients Czynniki ryzyka: • Wiek > 75 lat • Łagodna, umiarkowana lub ciężka niesprawność (potrzebna pomoc w gospodarstwie domowym i higienie osobistej) • Choroby współistniejące i

Open access